Denali Therapeutics (DNLI) Other Non-Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Other Non-Current Assets data on file, last reported at $26.2 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $26.2 million, down 2.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.2 million (down 2.65% YoY), and the FY2025 annual result was $25.9 million, up 4.84% from the prior year.
• Other Non-Current Assets grew to $26.2 million in Q1 2026 per DNLI's latest filing, from $25.9 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $50.6 million in Q2 2024 and troughed at $11.1 million in Q3 2023.
• A 5-year average of $23.0 million and a median of $23.0 million in 2025 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets surged 326.71% in 2022, then plunged 54.58% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $13.4 million in 2022, then surged by 35.41% to $18.1 million in 2023, then jumped by 36.37% to $24.7 million in 2024, then grew by 4.84% to $25.9 million in 2025, then climbed by 1.08% to $26.2 million in 2026.
• Business Quant data shows DNLI's Other Non-Current Assets at $26.2 million in Q1 2026, $25.9 million in Q4 2025, and $25.1 million in Q3 2025.